Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 10/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783256 | 0.97 | AVPR2 (0.55) | AVPR2ALDH1A1HPGDAVPR1AMAPT | |
| SCHEMBL6475340 | 0.93 | AVPR2 (0.52) | AVPR2AVPR1AMAPT | |
| SCHEMBL5785393 | 0.93 | AVPR2 (0.49) | AVPR2ALDH1A1AVPR1AMAPTTP53 | |
| SCHEMBL5785412 | 0.92 | AVPR2 (0.49) | AVPR2ALDH1A1AVPR1AMAPTTP53 | |
| SCHEMBL5785143 | 0.91 | AVPR2 (0.48) | AVPR2AVPR1AMAPT | |
| SCHEMBL5890975 | 0.90 | AVPR2 (0.47) | AVPR2ALDH1A1HPGDAVPR1AMAPT | |
| SCHEMBL5785436 | 0.90 | AVPR2 (0.47) | AVPR2ALDH1A1AVPR1AMAPTTP53 | |
| SCHEMBL5782658 | 0.90 | AVPR2 (0.47) | AVPR2AVPR1AMAPT | |
| SCHEMBL5891624 | 0.90 | ALDH1A1 (0.48) | AVPR2ALDH1A1HPGDMAPTTP53 | |
| SCHEMBL5784128 | 0.89 | AVPR2 (0.49) | AVPR2ALDH1A1AVPR1AMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377586-B1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2006-03-22 | — | — | EP | claimed |
| EP-1377586-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | claimed |
| WO-2002083678-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | claimed |
| US-7109193-B2 | Tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1377586-B1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | AVPR2 91/4885ALDH1A1 3354/4885HPGD 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.